Nordic Process
Chemistry Forum 2018

Frances Arnold is the Linus Pauling Professor of Chemical Engineering, Bioengineering and Biochemistry at Caltech, where her research focuses on protein engineering by directed evolution, with applications in alternative energy, chemicals, and medicine. Dr. Arnold pioneered the ‘directed evolution’ of proteins, mimicking Darwinian evolution in the laboratory to create new biological molecules. Her laboratory has developed protein evolution methods that are used widely in industry and basic science to engineer proteins with new and useful properties. Close

Previously we (micro-)structured the reactor to operate continuously – the new smart solution is to structure the process media alike the cell does with its organelles. Close

As Head of Process Research, Bayer AG Crop Science Division, Mark will highlight in his talk the challenges faced when progressing potential crop protection products from Research into Development. Nearly 25 years of process research experience serve as a backdrop for the presentation and discussion.
Close

Nick Turner obtained his DPhil in 1985 with Professor Sir Jack Baldwin and from 1985-1987 was a Royal Society Junior Research Fellow, spending time at Harvard University with Professor George Whitesides. He was appointed lecturer in 1987 at Exeter University and moved to Edinburgh in 1995, initially as a Reader and subsequently Professor in 1998. In October 2004 he joined Manchester University as Professor of Chemical Biology where his research group is located in the Manchester Institute of Biotechnology Biocentre (MIB: www.mib.ac.uk). He is Director of the Centre of Excellence in Biocatalysis (CoEBio3) (www.coebio3.org) and a Co-Director of SYNBIOCHEM, the BBSRC Synthetic Biology Research Centre. He is also a co-founder of Ingenza (www.ingenza.com). He is a member of the Editorial Board of ChemCatChem and Advanced Synthesis and Catalysis. His research interests are in the area of biocatalysis with particular emphasis on the discovery and development of novel enzyme catalysed reactions for applications in organic synthesis. His group are also interested in the application of directed evolution technologies for the development of biocatalysts with tailored functions.
Close

Stefan studied chemistry in Germany, France, and Switzerland. He obtained his PhD under the guidance of Prof. Dr. D. Seebach at the ETH Zurich in 1999. At Carbogen-Amcis, he had the pleasure to perform or supervise the GMP production of more than 80 Active Pharmaceutical Ingredients (API). In 2006, Stefan set up Chemical Process R&D at Actelion Pharmaceuticals Ltd, responsible for all scientific, technical, organizational, and budgetary aspects. His teams’ tasks were route finding and non-GMP production of APIs, and the development of 2nd generation routes for Actelion’s drugs. After the demerger with J&J on 16 June 2017, Stefan now heads Chemical Development at Idorsia Pharmaceuticals Ltd, adding to Chemical Process R&D the responsibility for development and GMP manufacturing of API’s from preclinical phase to commercial. Stefan has authored more than 65 scientific papers and patent applications and is a frequent speaker at conferences and universities, and in industry. In 2015, his team received the prestigious Sandmeyer Award by the Swiss Chemical Society. Close

David Cole-Hamilton was Professor of Chemistry in St. Andrews from 1985, becoming Emeritus in 2014. His main research interests concern the application of organometallic chemistry in homogeneous catalysis and materials chemistry. In homogeneous catalysis he develops: new reactions such as amide hydrogenation to amines, the use of bioresources such as waste natural oils and new methods for the post reaction separation of the product and the catalyst including using ionic liquids, supercritical fluids and flow processes. Close